Neuren Pharmaceuticals

(AI video summary)

This video was created on 14 January 2026 for IG audiences by ausbiz.

ASX code: NEU

Neuren Pharmaceuticals soars on Rett syndrome success

Neuren Pharmaceuticals is gaining significant attention in the biotech sector with its promising progress. The company forecasts generating around US$700 million in sales from its debut product by 2028. Developed specifically for Rett syndrome, this product has already received approval from the United States (US) Food and Drug Administration (FDA), offering patients diverse administration options. Neuren plans to expand further into European markets later this year.

Strategic partnerships and market response

In 2018, Neuren partnered with ACADIA Pharmaceuticals, securing an upfront payment of US$100 million. ACADIA handles marketing, allowing Neuren to focus on clinical trials in stages two and three. This partnership positions Neuren strongly with multiple projects in progress.

Positive updates from Neuren’s trials have led to a favourable market response, with shares rising by 5.5%. Analysts see potential for continued growth in the company’s share price, driven by more positive clinical outcomes. Compared to peers like Telix Pharmaceuticals, which face challenges with trials, Neuren is in a more favourable position.

Investment outlook

Neuren's vibrant market performance, including today's share price increase, highlights its potential. Nevertheless, analysts suggest investors to tread carefully, as sentiment can shift quickly in the volatile biotech sector.